CR10095A - Derivados de pirimidina para el tratamiento del crecimiento celular anormal - Google Patents
Derivados de pirimidina para el tratamiento del crecimiento celular anormalInfo
- Publication number
- CR10095A CR10095A CR10095A CR10095A CR10095A CR 10095 A CR10095 A CR 10095A CR 10095 A CR10095 A CR 10095A CR 10095 A CR10095 A CR 10095A CR 10095 A CR10095 A CR 10095A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- cellular growth
- abnormal cellular
- pirimidine derivatives
- derivatives
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title abstract 3
- 230000010261 cell growth Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto de fórmula 1 o una sal farmacéuticamente aceptable del mismo, en la que Ar es un grupo de fórmula y R1, R2, R13, A, K, M, L1, L2, X, Y1, Y2, Q, sal del mismo, en la que R1, R2, R13, A, K, L1, L2, W, X, Z, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p, y q son como se han definido en este documento. Dichos nuevos derivados de pirimidina son útiles en el tratamiento del crecimiento celular anormal, tal como cáncer, en mamíferos. Esta invención también se refiere a un procedimiento de uso de dichos compuestos en el tratamiento del crecimiento celular anormal en mamíferos, especialmente seres humanos, y a composiciones farmacéuticas que contienen dichos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75270805P | 2005-12-21 | 2005-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10095A true CR10095A (es) | 2008-07-17 |
Family
ID=38038639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10095A CR10095A (es) | 2005-12-21 | 2008-06-20 | Derivados de pirimidina para el tratamiento del crecimiento celular anormal |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7820648B2 (es) |
| EP (1) | EP1966207A2 (es) |
| JP (1) | JP4332590B2 (es) |
| KR (1) | KR101060051B1 (es) |
| CN (1) | CN101346380B (es) |
| AP (1) | AP2008004488A0 (es) |
| AR (1) | AR058399A1 (es) |
| AU (1) | AU2006327871A1 (es) |
| BR (1) | BRPI0620324A2 (es) |
| CA (1) | CA2634646C (es) |
| CR (1) | CR10095A (es) |
| DO (1) | DOP2006000289A (es) |
| EA (1) | EA014551B1 (es) |
| EC (1) | ECSP088563A (es) |
| GT (1) | GT200600517A (es) |
| HN (1) | HN2006042221A (es) |
| IL (1) | IL191555A0 (es) |
| MA (1) | MA30075B1 (es) |
| ME (1) | MEP0908A (es) |
| NL (1) | NL2000375C2 (es) |
| NO (1) | NO20082338L (es) |
| PE (1) | PE20071138A1 (es) |
| RS (1) | RS20080272A (es) |
| SV (1) | SV2008002969A (es) |
| TN (1) | TNSN08270A1 (es) |
| TW (1) | TW200736258A (es) |
| UA (1) | UA89123C2 (es) |
| UY (1) | UY30051A1 (es) |
| WO (1) | WO2007072158A2 (es) |
| ZA (1) | ZA200804488B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005012294A1 (en) | 2003-07-30 | 2005-02-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| CA2654670A1 (en) * | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | New compounds |
| ES2555803T3 (es) | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
| CN101678215B (zh) | 2007-04-18 | 2014-10-01 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
| CN101903357A (zh) * | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | 作为pkc抑制剂的环状胺取代的嘧啶二胺 |
| US8461147B2 (en) * | 2007-12-03 | 2013-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| UY31714A (es) * | 2008-03-20 | 2009-11-10 | Boehringer Ingelheim Int | Preparación selectiva de pirimidinas sustituidas |
| US8372974B2 (en) * | 2008-03-20 | 2013-02-12 | Boehringer Ingelheim International Gmbh | Regioselective preparation of substituted pyrimidines |
| WO2009153589A1 (en) | 2008-06-17 | 2009-12-23 | Astrazeneca Ab | Pyridine compounds |
| EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
| US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| WO2011018517A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
| US8466155B2 (en) * | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
| TWI513694B (zh) | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
| US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| EP2646448B1 (en) | 2010-11-29 | 2017-08-30 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
| DK2688883T3 (en) | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
| US9458154B2 (en) | 2011-12-09 | 2016-10-04 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
| CN104169272A (zh) | 2011-12-23 | 2014-11-26 | 赛尔佐姆有限公司 | 作为激酶抑制剂的嘧啶-2,4-二胺衍生物 |
| CN103655577A (zh) * | 2012-09-20 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103664957A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN105130907B (zh) * | 2015-07-29 | 2018-10-16 | 沈阳药科大学 | 嘧啶类化合物及其用途 |
| US11168068B2 (en) | 2016-07-18 | 2021-11-09 | Janssen Pharmaceutica Nv | Tau PET imaging ligands |
| WO2020023851A1 (en) * | 2018-07-26 | 2020-01-30 | Yale University | Bifunctional substitued pyrimidines as modulators of fak proteolyse |
| US20240025887A1 (en) * | 2021-01-07 | 2024-01-25 | Ontario Institute For Cancer Research (Oicr) | Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
| WO2022147622A1 (en) * | 2021-01-07 | 2022-07-14 | Ontario Institute For Cancer Research (Oicr) | Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
| JP2024525368A (ja) * | 2021-07-01 | 2024-07-12 | エアリー ファーマシューティカルズ インコーポレイテッド | アゼチジニルピリミジンおよびその使用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| JP2006508997A (ja) * | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用 |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| US20040242613A1 (en) * | 2003-01-30 | 2004-12-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of PKC-theta |
| JP2007537238A (ja) * | 2004-05-14 | 2007-12-20 | ファイザー・プロダクツ・インク | 異常細胞増殖の治療のためのピリミジン誘導体 |
| BRPI0511138A (pt) * | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina para o tratamento de desenvolvimento celular anormal |
-
2006
- 2006-12-11 CA CA2634646A patent/CA2634646C/en not_active Expired - Fee Related
- 2006-12-11 UA UAA200807169A patent/UA89123C2/ru unknown
- 2006-12-11 JP JP2008546669A patent/JP4332590B2/ja not_active Expired - Fee Related
- 2006-12-11 BR BRPI0620324-8A patent/BRPI0620324A2/pt not_active IP Right Cessation
- 2006-12-11 WO PCT/IB2006/003655 patent/WO2007072158A2/en not_active Ceased
- 2006-12-11 KR KR1020087017637A patent/KR101060051B1/ko not_active Expired - Fee Related
- 2006-12-11 CN CN2006800487340A patent/CN101346380B/zh not_active Expired - Fee Related
- 2006-12-11 AU AU2006327871A patent/AU2006327871A1/en not_active Abandoned
- 2006-12-11 EA EA200801287A patent/EA014551B1/ru not_active IP Right Cessation
- 2006-12-11 AP AP2008004488A patent/AP2008004488A0/xx unknown
- 2006-12-11 EP EP06831737A patent/EP1966207A2/en not_active Withdrawn
- 2006-12-11 RS RSP-2008/0272A patent/RS20080272A/sr unknown
- 2006-12-11 ME MEP-09/08A patent/MEP0908A/xx unknown
- 2006-12-14 NL NL2000375A patent/NL2000375C2/nl not_active IP Right Cessation
- 2006-12-19 DO DO2006000289A patent/DOP2006000289A/es unknown
- 2006-12-19 GT GT200600517A patent/GT200600517A/es unknown
- 2006-12-20 PE PE2006001661A patent/PE20071138A1/es not_active Application Discontinuation
- 2006-12-20 HN HN2006042221A patent/HN2006042221A/es unknown
- 2006-12-20 TW TW095147907A patent/TW200736258A/zh unknown
- 2006-12-20 US US11/613,390 patent/US7820648B2/en not_active Expired - Fee Related
- 2006-12-20 AR ARP060105660A patent/AR058399A1/es not_active Application Discontinuation
- 2006-12-21 UY UY30051A patent/UY30051A1/es not_active Application Discontinuation
-
2008
- 2008-05-19 IL IL191555A patent/IL191555A0/en unknown
- 2008-05-22 NO NO20082338A patent/NO20082338L/no not_active Application Discontinuation
- 2008-05-23 ZA ZA200804488A patent/ZA200804488B/xx unknown
- 2008-06-19 EC EC2008008563A patent/ECSP088563A/es unknown
- 2008-06-20 TN TNP2008000270A patent/TNSN08270A1/fr unknown
- 2008-06-20 MA MA31059A patent/MA30075B1/fr unknown
- 2008-06-20 SV SV2008002969A patent/SV2008002969A/es not_active Application Discontinuation
- 2008-06-20 CR CR10095A patent/CR10095A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR10095A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| HN2005000212A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| BRPI0607455A2 (pt) | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica | |
| ECSP066406A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| ECSP099803A (es) | Derivados de bencimidazol | |
| CL2007003627A1 (es) | Compuestos derivados de 3-h-pirazolopiridinas; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades de crecimiento vascular desregulado tal como leucemia mielogena aguda, retinopatia, artritis reumatoide, psorias | |
| AR053412A1 (es) | Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos | |
| ECSP10010346A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis | |
| BRPI0518459A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
| ECSP099480A (es) | Compuestos químicos 637: piridopirimidindionas como inhibidores de la pde4 | |
| ECSP078062A (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
| PT2049480E (pt) | Derivados de 2-arilindole como inibidores da mpges-i | |
| MX2007013624A (es) | Inhibidores de proteina cinasa. | |
| CR10199A (es) | Derivados de benzimidazol | |
| CR8749A (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo | |
| UY29343A1 (es) | Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso. | |
| CU20080126A7 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| ATE425948T1 (de) | Substituierte hydroxyacetophenonderivative | |
| NI200500205A (es) | "derivados de pirimidina para el tratamiento del crecimiento celular anorma." | |
| UA93313C2 (en) | Benzimidazole derivatives | |
| UY29566A1 (es) | "derivados de piperidina, composiciones farmaccuticas que los contienen, procedimientos de preparacinn y su uso" | |
| UY28136A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| DOP2005000086A (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo | |
| TH105256A (th) | อนุพันธ์ไพริมิดีนสำหรับการรักษาการเจริญเติบโตของเซล์ที่ผิดปกติ | |
| CU23702B7 (es) | Composiciones fungicidas |